Scarica l'app Stockscreener
0.00
100.00%
-10.14
Precedente Chiudi:
$10.14
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$N/A
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$11.99
Ac Immune Sa Stock (AACIU) Company Profile
Nome
Ac Immune Sa
Settore
Industria
Telefono
215.543.6886
Indirizzo
89 NEXUS WAY, CARMANA BAY
Compare AACIU vs VRTX, REGN, MRNA, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AACIU
Ac Immune Sa
|
0.00 | 0 | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
512.17 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.72 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
166.57 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
992.58 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
365.85 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ac Immune Sa Borsa (AACIU) Ultime notizie
AC Immune’s New Phase 1 NLRP3 Trial Puts Inflammation Strategy in Focus - TipRanks
AC Immune SA (NASDAQ: ACIU) Schedules October 2 Vote for Tom Graney's Board Nomination - Kalkine Media
AC Immune Calls October EGM to Add Veteran Biopharma Financier Tom Graney to Board - TipRanks
Parkinson's drug Fast Tracked as AC Immune (NASDAQ: ACIU) plans board changes - Stock Titan
AC Immune Ltd (NASDAQ: ACIU) Share Price, ACIU Stock News, ACIU Share Price & Updates - kalkine.ca
AC Immune2026 Funding Rounds & List of Investors - Tracxn
AC Immune reports positive phase 1 data for ACI‑19764 - PharmaTimes
AC Immune stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Positive Ph1 results for AC Immune's NLRP3 inflammasome inhibitor - pharmaphorum
Stifel’s Thomas Shrader Reiterates Buy on AC Immune, Citing Diversified Neuroscience Pipeline, Promising NLRP3 Data, and Strong Cash Runway - TipRanks
AC (ACIU) Financial Update: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Market Price Moves 2.33% Higher on the DayConsensus Forecast Report - vinanet.vn
AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline - Benzinga
ACIU Reiterated by BTIG -- Price Target Maintained at $8.00 - GuruFocus
AC Immune's NLRP3 inhibitor reaches brain with safety intact in first human study - AllSci
AC Immune shares rise after encouraging early Phase 1 data for ACI-19764 - Yahoo Finance
AC Immune stock gains on early Phase 1 trial results By Investing.com - Investing.com Australia
AC Immune stock gains on early Phase 1 trial results - Investing.com
AC Immune posts trial data for inflammatory drug (ACIU:NASDAQ) - Seeking Alpha
AC Immune reports phase 1 safety data for NLRP3 inhibitor By Investing.com - Investing.com Nigeria
AC Immune posts positive first‑in‑human data for NLRP3 inhibitor ACI‑19764 - TipRanks
AC Immune reports phase 1 safety data for NLRP3 inhibitor - Investing.com India
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 - The Manila Times
AC Immune (NASDAQ: ACIU) advances NLRP3 pill into heart-risk trial - Stock Titan
AC (ACIU) Levels: Advances 0.39% to $2.58 in the Latest Reading; Chart View: $2.45 and $2.71 Define the Nearby Reference LevelsInside Day Breakout - vinanet.vn
AC Immune takes Parkinson's vaccine into US trials as Phase II data near - AllSci
ACIU Q2 2026 Earnings: Surprise EPS Beat of 117.61% Offers Little Support as Shares Slip 1.91%Quarterly Financial Update - vinanet.vn
ACIU Looks 33.6% Undervalued on GF Value™ Despite Financial Chal - GuruFocus
AC Immune receives FDA fast track status for parkinson’s drug By Investing.com - Investing.com Nigeria
AC Immune Wins FDA Fast Track for ACI-7104 in Early Parkinson’s Disease - TipRanks
AC Immune receives FDA fast track status for parkinson’s drug - Investing.com
AC Immune (NASDAQ: ACIU) gains FDA Fast Track, IND clearance for Parkinson’s drug ACI-7104 - Stock Titan
AC Immune’s Parkinson’s Candidate Shows 100% Responder Rate - Stock Titan
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD) - Yahoo Finance UK
AC Immune SA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - simplywall.st
Analyst Reiterates Buy on AC Immune as 2H26 Catalysts Approach; Price Target Maintained at $12 - tipranks.com
AC Immune (NasdaqGM:ACIU) Stock Price Shrugs Off Surprise Quarterly Profit - Sahm
ACIU Reiterated by BTIG -- Maintains Price Target at $8.00 - GuruFocus
AC Immune SA reports results for the quarter ended June 30Earnings Summary - TradingView
AC Immune Files First-Half 2026 Results and Corporate Update on Form 6-K - TipRanks
AC Immune: Q2 Earnings Snapshot - Barchart.com
AC Immune First Half 2026 Financial and Corporate Update - The Manila Times
Partner milestones lift AC Immune (NASDAQ: ACIU) cash and cut loss - Stock Titan
AC Immune’s Parkinson’s Trial Gets a $4 Million Grant - Stock Titan
AC Immune (ACIU) Posts Modest 2.2% Gain as Shares Trade Above $2.30 SupportMFI Overbought - dars.gov.et
ACIU Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesAnalyst Drop Coverage - vinanet.vn
ACIU Q1 2026 Earnings: Modest EPS Beat Drives 4.41% Share Gain for Clinical-Stage Alzheimer's DeveloperPost-Earnings Drift - vinanet.vn
ACIU Q1 2026 Earnings: Narrowed Loss Beats Expectations as Pipeline AdvancesPretax Income Report - vinanet.vn
AC Immune SA (ACIU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AC Immune SA (ACIU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AC Immune SA (ACIU) Institutional Confidence - TradingKey
Ac Immune Sa Azioni (AACIU) Dati Finanziari
Non sono disponibili dati finanziari per Ac Immune Sa (AACIU). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.16%
2.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):